Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

<p>Abstract</p> <p>Background</p> <p>The once-weekly (QW) formulation of the glucagon-like peptide-1 receptor agonist exenatide has been demonstrated to improve A1C, fasting plasma glucose (FPG), body weight, serum lipid profiles, and blood pressure in patients with typ...

Full description

Bibliographic Details
Main Authors:	Pencek Richard, Han Jenny, Gurney Kate, Taylor Kristin, Walsh Brandon, Trautmann Michael
Format:	Article
Language:	English
Published:	BMC 2011-04-01
Series:	BMC Endocrine Disorders
Online Access:	http://www.biomedcentral.com/1472-6823/11/9

Similar Items

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
by: MacConell L, et al.
Published: (2013-01-01)

Exenatide once weekly: clinical outcomes and patient satisfaction
by: Biju Jose1, et al.
Published: (2010-08-01)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders WB, et al.
Published: (2016-07-01)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
by: MacConell L, et al.
Published: (2015-05-01)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
by: Goud A, et al.
Published: (2015-10-01)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
by: Inaishi J, et al.
Published: (2022-02-01)

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
by: Gaebler JA, et al.
Published: (2012-04-01)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
by: Timothy M. E. Davis, et al.
Published: (2022-06-01)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
by: Yuusuke Watanabe, et al.
Published: (2020-03-01)

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study
by: Carol H Wysham, et al.
Published: (2020-04-01)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
by: Mann KV, et al.
Published: (2014-06-01)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Jason Seewoodhary, et al.
Published: (2010-05-01)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Seewoodhary J, et al.
Published: (2010-05-01)

Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study
by: Jun Inaishi, et al.
Published: (2022-01-01)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
by: Chiquette E, et al.
Published: (2012-11-01)

Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
by: Deng W, et al.
Published: (2015-08-01)

EXSCEL—once-weekly exenatide reduces medical resource utilization in patients with type 2 diabetes mellitus
by: Reed, S, et al.
Published: (2018)

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
by: Mette Kruse Klausen, et al.
Published: (2022-10-01)

The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
by: Bruce Wang, et al.
Published: (2015-01-01)

Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
by: Becker, F, et al.
Published: (2018)

Hypothyroidism Could be a Potential Factor to Prolong Subcutaneous Nodules of Exenatide once Weekly: A Case Report
by: Ayako Ito, MD, et al.
Published: (2019-05-01)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
by: Rasmus Stenlid, et al.
Published: (2023-11-01)

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial
by: Becker, F, et al.
Published: (2021)

Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
by: Robert J. Mentz, et al.
Published: (2018-10-01)

GLYCEMIC AND NON-GLYCEMIC EFFECTS OF EXENATIDE IN PATIENTS WITH DIABETES MELLITUS OF TYPE 2 (DM2) WITH MYOCARDIAL INFARCTION
by: A. Yu. BABENKO, et al.
Published: (2016-12-01)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin
by: Zinman, B, et al.
Published: (2011)

An antiinflammatory actions of exenatide
Published: (2012-12-01)

Comparison of different dosing regimens (once weekly <it>vs</it>. twice weekly, and once weekly <it>vs</it>. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
by: Macdougall Iain C
Published: (2007-11-01)

Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
by: Peng Wang, et al.
Published: (2024-01-01)

Effect of once weekly oral levothyroxine therapy
by: Andrea del Toro-Diez, et al.
Published: (2021-07-01)

Long-acting preparations of exenatide
by: Cai Y, et al.
Published: (2013-09-01)

Greater Attendance at a Community Weight Loss Programme over the First 12 Weeks Predicts Weight Loss at 2 Years
by: Carmen Piernas, et al.
Published: (2020-08-01)

Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women
by: Megan Rodgers, et al.
Published: (2021-11-01)

Successful and unsuccessful weight-loss maintainers: strategies to counteract metabolic compensation following weight loss
by: Louise D. Clamp, et al.
Published: (2018-01-01)

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
by: Giulia Di Dalmazi, et al.
Published: (2022-07-01)

Once-a-week versus once-every-3-weeks cisplatin in patients receiving chemoradiation for locally advanced head-and-neck cancer: A survey of practice in India
by: Gautam Goyal, et al.
Published: (2018-01-01)

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
by: Robinson, L, et al.
Published: (2013)

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
by: Robinson, L, et al.
Published: (2013)

The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
by: İlker Çorapçı, et al.
Published: (2004-03-01)